Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...
Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...
Zacks Investment Research on MSN
Will Keytruda continue to aid Merck's top line in Q1 earnings?
A significant share of Merck’s MRK revenues is derived from the oncology portfolio, led by its blockbuster PD-L1 inhibitor, ...
Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...
First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...
A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...
Keytruda, manufactured by the US-based Merck & Co, is an immunotherapy drug that has become one of the world’s best-selling ...
What is the Cancer Calculus investigation? The Cancer Calculus is a yearlong investigation by the International Consortium of ...
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...
Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells.
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results